2023+NICE指南：心血管疾病的风险评估和降低包括脂质修饰英文版NG.238）.pdf

《2023+NICE指南：心血管疾病的风险评估和降低包括脂质修饰英文版NG.238）.pdf》由会员分享，可在线阅读，更多相关《2023+NICE指南：心血管疾病的风险评估和降低包括脂质修饰英文版NG.238）.pdf（48页珍藏版）》请在周易易学书店|道易五术书社上搜索。

1、Car dio v ascular dise ase:risk assessmen t and r e duc tion,including lipid modific a tion NICE guideline Published:14 December 2023 www.nice.org.uk/guidance/ng238 NICE 2023.All rights reserved.Subject to Notice of rights(https:/www.nice.org.uk/terms-and-conditions#notice-of-rights).Y our r esponsi

2、 bili t y The recommendations in this guideline represent the view of NICE,arrived at after careful consideration of the evidence available.When exercising their judgement,professionals and practitioners are expected to take this guideline fully into account,alongside the individual needs,preference

3、s and values of their patients or the people using their service.It is not mandatory to apply the recommendations,and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual,in consultation with them and their families and carers or gua

4、rdian.All problems(adverse events)related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.Local commissioners and providers of healthcare have a responsibility to enable th

5、e guideline to be applied when individual professionals and people using services wish to use it.They should do so in the context of local and national priorities for funding and developing services,and in light of their duties to have due regard to the need to eliminate unlawful discrimination,to a

6、dvance equality of opportunity and to reduce health inequalities.Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and

7、 should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.Cardiovascular disease:risk assessment and reduction,including lipid modification(NG238)NICE 2023.All rights reserved.Subject to Notice of rights(https:/www.nice.org.uk/terms-and-conditions#noti

8、ce-of-rights).Page 2 of48Con ten ts Overview.5 Who is it for?.5 Recommendations.6 1.1 Identifying and assessing cardiovascular disease risk for people without established cardiovascular disease.6 1.2 Aspirin for primary prevention of cardiovascular disease.10 1.3 Lifestyle changes for the primary an

9、d secondary prevention of cardiovascular disease.10 1.4 Initial lipid measurement and referral for specialist review.13 1.5 Discussions and assessment before starting statins.14 1.6 Statins for primary prevention of cardiovascular disease.17 1.7 Lipid-lowering treatment for secondary prevention of c

10、ardiovascular disease.19 1.8 Statins for primary and secondary prevention of cardiovascular disease in people with chronic kidney disease.22 1.9 Optimising treatment for people on statins.23 1.10 Statins are contraindicated or not tolerated.24 1.11 Assessing response to treatment.25 1.12 Lipid-lower

11、ing treatments that should not be used or not used routinely.27 Terms used in this guideline.29 Recommendations for research.31 1 Simplifying risk assessment.31 2 Statin treatment for older people.31 3 Lipid-lowering treatment for people with type 1 diabetes.31 Rationale and impact.32 Full formal ri

12、sk assessment.32 Communication about risk assessment,lifestyle changes and treatment.34 Aspirin for primary prevention of cardiovascular disease.35 Cardioprotective diet.36 Discussions and assessment before starting statins.36 Cardiovascular disease:risk assessment and reduction,including lipid modi

13、fication(NG238)NICE 2023.All rights reserved.Subject to Notice of rights(https:/www.nice.org.uk/terms-and-conditions#notice-of-rights).Page 3 of48Statins for primary prevention of cardiovascular disease.37 Statins for secondary prevention of cardiovascular disease.39 Optimising treatment for people

14、on statins.40 Lipid target for secondary prevention of cardiovascular disease.40 Assessing response to treatment.44 Context.46 Finding more information and committee details.47 Update information.48 Cardiovascular disease:risk assessment and reduction,including lipid modification(NG238)NICE 2023.All

15、 rights reserved.Subject to Notice of rights(https:/www.nice.org.uk/terms-and-conditions#notice-of-rights).Page 4 of48This guideline replaces CG181.This guideline is the basis of QS5,QS100,QS208 and QS209.Ov er vie w This guideline covers identifying and assessing risk of cardiovascular disease(CVD)

16、in adults without established CVD.It covers lifestyle changes and lipid-lowering treatment(including statins)for primary and secondary prevention of CVD,and includes guidance for people who also have diabetes or chronic kidney disease.W ho is i t f or?Healthcare professionals Adults who are at risk

17、of CVD or who have CVD Cardiovascular disease:risk assessment and reduction,including lipid modification(NG238)NICE 2023.All rights reserved.Subject to Notice of rights(https:/www.nice.org.uk/terms-and-conditions#notice-of-rights).Page 5 of48R e c ommenda tions People have the right to be involved i

18、n discussions and make informed decisions about their care,as described in NICEs information on making decisions about your care.Making decisions using NICE guidelines explains how we use words to show the strength(or certainty)of our recommendations,and has information about prescribing medicines(i

19、ncluding off-label use),professional guidelines,standards and laws(including on consent and mental capacity),and safeguarding.1.1 I den tif ying and assessing c ar dio v ascular dise ase risk f or pe op le wi thou t estab lishe d c ar dio v ascular dise ase I den tif ying pe op le f or full f ormal

20、risk assessmen t 1.1.1 For the primary prevention of cardiovascular disease(CVD)in primary care,use a systematic strategy to identify people who are likely to be at high risk of CVD.2008,amended 2014 1.1.2 Prioritise people based on an estimate of their CVD risk before doing a full formal risk asses

21、sment.Estimate their CVD risk using CVD risk factors already recorded in primary care electronic medical records.2008 1.1.3 Review estimates of CVD risk on an ongoing basis for people over 40.2008 1.1.4 Prioritise people for a full formal risk assessment if their estimated 10-year risk of CVD is 10%

22、or more.2008,amended 2014 1.1.5 Discuss the process of risk assessment with the person identified as being at risk,including the option of declining any formal risk assessment.2008 Cardiovascular disease:risk assessment and reduction,including lipid modification(NG238)NICE 2023.All rights reserved.S

23、ubject to Notice of rights(https:/www.nice.org.uk/terms-and-conditions#notice-of-rights).Page 6 of481.1.6 Do not use opportunistic assessment as the main strategy in primary care to identify CVD risk in unselected people.2008 F ull f ormal risk assessmen t 1.1.7 Use the QRISK3 tool to calculate the

24、estimated CVD risk within the next 10 years for people aged between 25 and 84 without CVD.May 2023 1.1.8 Use the QRISK3 tool for people with type 2 diabetes aged between 25 and 84.May 2023 Until electronic clinical systems in which QRISK2 is embedded are updated with QRISK3,it may be necessary to us

25、e QRISK2.When assessing risk for people taking corticosteroids or atypical antipsychotics or people with systemic lupus erythematosus,migraine,severe mental illness or erectile dysfunction,use QRISK3(the online version of QRISK3,if necessary)because QRISK2 does not take these risk factors into accou

26、nt and may underestimate the 10-year CVD risk in these populations.1.1.9 Do not use a risk assessment tool for people who are at high risk of CVD,including people with:type 1 diabetes(see the section on primary prevention of CVD for people with type 1 diabetes)an estimated glomerular filtration rate

27、 less than 60 ml per minute per 1.73 m2 and/or albuminuria(see the section on primary and secondary prevention of CVD for people with chronic kidney disease CKD)familial hypercholesterolaemia(see NICEs guideline on familial hypercholesterolaemia)or other inherited disorders of lipid metabolism.May 2

28、023 1.1.10 Recognise that CVD risk tools may underestimate risk in certain groups of people,including but not limited to:Cardiovascular disease:risk assessment and reduction,including lipid modification(NG238)NICE 2023.All rights reserved.Subject to Notice of rights(https:/www.nice.org.uk/terms-and-

29、conditions#notice-of-rights).Page 7 of48 people treated for HIV people already taking medicines to treat CVD risk factors people who have recently stopped smoking people taking medicines that can cause dyslipidaemia,such as immunosuppressant drugs people with severe mental illness people with autoim

30、mune disorders,and other systemic inflammatory disorders.May 2023 1.1.11 Consider people aged 85 or older to be at increased risk of CVD because of age alone,particularly people who smoke or have raised blood pressure.May 2023 For a short explanation of why the committee made these recommendations a

31、nd how they might affect practice,see the rationale and impact section on full formal risk assessment.Full details of the evidence and the committees discussion are in evidence review A:CVD risk assessment tools:primary prevention.Comm unic a tion abou t risk assessmen t,lif est y le chang es and tr

32、 e a tmen t 1.1.12 Follow the recommendations on communication in NICEs guidelines on patient experience in adult NHS services and shared decision making.2014 1.1.13 Set aside adequate time during the consultation to provide information on risk assessment and to answer any questions.Arrange for furt

33、her consultation if needed.2008,amended May 2023 1.1.14 Document the discussion relating to the consultation on risk assessment and the persons decision.2008 Cardiovascular disease:risk assessment and reduction,including lipid modification(NG238)NICE 2023.All rights reserved.Subject to Notice of rig

34、hts(https:/www.nice.org.uk/terms-and-conditions#notice-of-rights).Page 8 of481.1.15 Offer people information about their absolute risk of CVD and the absolute benefits and harms of any intervention over a 10-year period.2008 1.1.16 Consider using a lifetime risk tool such as QRISK3-lifetime to infor

35、m discussions on CVD risk and to motivate lifestyle changes,particularly for people with a 10-year QRISK3 score less than 10%,and people under 40 who have CVD risk factors.May 2023 1.1.17 To encourage the person to participate in reducing their CVD risk:find out what,if anything,the person has alrea

36、dy been told about their CVD risk and how they feel about it explore the persons beliefs about what determines future health(this may affect their attitude to changing risk)assess their readiness to make changes to their lifestyle(diet,physical activity,smoking and alcohol consumption),to undergo in

37、vestigations and to take long-term medication assess their confidence to make changes to their lifestyle,undergo investigations and take medication inform them of potential future management options based on current evidence and best practice involve them in developing a shared management plan check

38、 that they have understood what has been discussed.2008,amended 2014 1.1.18 If the persons CVD risk is at a level where treatment is recommended but they decline the offer of treatment,advise them that their CVD risk should be reassessed in the future.Record their choice in their medical records.200

39、8,amended 2014 Cardiovascular disease:risk assessment and reduction,including lipid modification(NG238)NICE 2023.All rights reserved.Subject to Notice of rights(https:/www.nice.org.uk/terms-and-conditions#notice-of-rights).Page 9 of48For a short explanation of why the committee made the 2023 recomme

40、ndation and how it might affect practice,see the rationale and impact section on communication about risk assessment,lifestyle changes and treatment.Full details of the evidence and the committees discussion are in evidence review A:CVD risk assessment tools:primary prevention.1.2 A spirin f or prim

41、ar y pr e v en tion o f c ar dio v ascular dise ase 1.2.1 Do not routinely offer aspirin for primary prevention of CVD.January 2023 For guidance on using aspirin to prevent venous thromboembolism in over 16s in hospital,see NICEs guideline on venous thromboembolism in over 16s:reducing the risk of h

42、ospital-acquired deep vein thrombosis or pulmonary embolism.NICEs surveillance team reviewed the evidence about aspirin for the primary prevention of CVD.Based on the review,NICE decided to add a do not routinely offer recommendation about this.For full details,see the January 2023 exceptional surve

43、illance report.1.3 Lif est y le chang es f or the primar y and se c ondar y pr e v en tion o f c ar dio v ascular dise ase Beha viour chang e 1.3.1 Advise and support people at high risk of or with CVD to achieve a healthy lifestyle in line with NICEs guideline on behaviour change:general approaches

44、.2014,amended May 2023 Cardiovascular disease:risk assessment and reduction,including lipid modification(NG238)NICE 2023.All rights reserved.Subject to Notice of rights(https:/www.nice.org.uk/terms-and-conditions#notice-of-rights).Page 10 of48H e al th y e a ting For advice on healthy eating,see the

45、 NHS eat well guide.Car diopr ote c ti v e die t 1.3.2 Advise people at high risk of or with CVD to eat a diet in which total fat intake is 30%or less of total energy intake,saturated fats are 7%or less of total energy intake,and where possible saturated fats are replaced by mono-unsaturated and pol

46、yunsaturated fats.May 2023 1.3.3 Advise people at high risk of or with CVD to:reduce their saturated fat intake increase their mono-unsaturated fat intake with olive oil,rapeseed oil or spreads based on these oils and to use them in food preparation.2014 1.3.4 Take account of a persons individual ci

47、rcumstances,for example,drug treatment,comorbidities and other lifestyle changes,when giving dietary advice.2014 For a short explanation of why the committee made the 2023 recommendation and how it might affect practice,see the rationale and impact section on cardioprotective diet.Full details of th

48、e evidence and the committees discussion are in evidence review B:dietary cholesterol strategies.P h ysic al ac ti vi t y 1.3.5 Advise people at high risk of or with CVD to do aerobic and muscle-strengthening activities in line with the UK Chief Medical Officers physical activity guidelines.2008,ame

49、nded 2014 1.3.6 Encourage people who are unable to perform moderate intensity physical activity Cardiovascular disease:risk assessment and reduction,including lipid modification(NG238)NICE 2023.All rights reserved.Subject to Notice of rights(https:/www.nice.org.uk/terms-and-conditions#notice-of-righ

50、ts).Page 11 of48because of comorbidity,medical conditions or personal circumstances to exercise at their maximum safe capacity.2008,amended 2014 1.3.7 Advice about physical activity should take into account the persons needs,preferences and circumstances.Agree goals and provide the person with writt